Navigation Links
BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance

WOBURN, Mass., Aug. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Thaddeus Pullano, 53, as Vice President of Quality Assurance.

(Photo: )

Previously, Dr. Pullano served as the Vice President of Quality Systems for Acambis from 2003 to 2007. In this role, he was responsible for all aspects of Quality Systems, including oversight of vaccine manufacturing and clinical quality assurance. Prior to joining Acambis, Dr. Pullano was responsible for quality assurance at Transkaryotic Therapies as the Company transitioned from R&D to manufacturing operations. He has also held a number of positions in quality assurance at Wyeth Vaccines. Dr. Pullano holds a Ph.D. in Biochemistry from the University of Southern California and a BS in Biochemistry from the State University of New York at Binghamton.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Thad has direct and extensive experience with quality systems supporting the manufacture and release of biologics for clinical trials and commercial sale. He becomes part of the core team dedicated to moving our Woburn manufacturing facility, which will supply Phase III and launch grade material, towards operational status."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX(GM-CSF), is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX(GM-CSF) has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX(GM-CSF) as stand alone therapy in patients with stage IIIc and stage IV metastatic disease.

The Company's second program is a vaccine for genital herpes, ImmunoVEX(HSV2), which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX(HSV2) is scheduled to initiate later this year.

For more information visit the company's website at


Copyright©2007 PR Newswire.

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
(Date:10/13/2015)... ... , ... The shortlist of finalists for the Pistoia Alliance President’s Startup Challenge ... from across Europe and the USA. , The Startup Challenge 2015 has seen startup ... in life sciences R&D, with over 30 entries submitted. A panel of expert judges ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Universal SuperHeat Controller/Sensor (USHX) product, launches today on the Android smartphone platform. Southern ... system with DMQ’s remote control and monitoring capability for the first time to ...
(Date:10/13/2015)... , Oct. 13, 2015  Amgen (NASDAQ: ... and Cocoon Biotech, Inc. are Amgen,s 2015 selection for ... space at LabCentral. LabCentral is an innovative, shared laboratory ... startups. Cambridge, Mass. ... ways to deliver potential life-changing therapies. --> ...
(Date:10/13/2015)... SUNNYVALE, Calif. , Oct. 13, 2015  Cepheid ... the quarter ending September 30, 2015. ... financial results, total revenue for the third quarter of ... net loss per share is expected to be approximately ... financial results, non-GAAP net loss per share for the ...
Breaking Biology Technology:
(Date:10/13/2015)... MATEO, Calif. , Oct. 13, 2015 ... real-time, machine-based learning to analyze big data and minimize ... today with Emailage , an innovative fraud prevention ... leverage transactional risk based on a user,s email address. ... a machine learning solution that combines email risk assessment ...
(Date:10/13/2015)... 13, 2015 Dragon Capital Group Corp. ... China , announced today that its wholly ... received a contract for Multi-Format Naked Eye 3D System for ... $450,000 for the project that is expected to be completed ... 35% in gross profits. --> ...
(Date:10/13/2015)... , Oct. 7, 2015 Research and ... the "India Biometrics Authentication & Identification Market - ... --> --> ... $823.46 million in 2014 to $2.06 billion in 2020 ... 2020. India . Growing ...
Breaking Biology News(10 mins):